|
Contra-indications, warnings, etc
75 - 100% of animals vaccinated with Bravoxin 10 may experience reactions to vaccination.
Most commonly reported reactions are localised swelling or induration at the injection site but may also include mild hyperthermia, abscess or other reaction in the underlying tissues at the injection site.
Swelling at the injection site occurs in the majority of animals. This may reach up to a mean value of 6 cm in sheep and 15 cm diameter in cattle; occasionally reactions of up to 25 cm diameter may be seen in cattle. Most local reactions resolve within 3-6 weeks in sheep and in less than 10 weeks in cattle, but may persist longer in a minority of animals.
An abscess may develop in some animals. Vaccination may give rise to reactions in the underlying tissues at the injection site.
Skin discolouration at the injection site (which returns to normal as the local reaction resolves) may occur.
Localised pain at the injection site for 1-2 days post first vaccination may occur.
The local reactions do not affect the general health, demeanour, feeding or weight gain of the animals.
If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.
In calves and lambs, local reactions may increase slightly if twice the recommended dose is administered.
Special warnings
In the event of an anaphylactic reaction appropriate treatment such as adrenaline should be administered without delay.
Do not vaccinate sick or immunodeficient animals.
No side effects other than those already described were seen when the vaccine was used in sheep and cattle between 8 and 2 weeks prior to parturition. In the absence of specific data, no recommendation can be made for use of the vaccine during the first or second third of pregnancy.
Avoid stress in pregnant ewes and cows.
The effectiveness of the vaccine in providing passive immunity to young lambs and calves depends on these animals ingesting adequate amounts of colostrum on the first day of life.
Clinical trials have demonstrated that the presence of maternal antibodies (MDA), particularly against C. tetani, C. novyi type B, C. perfringens type A (calves only), C. chauvoei (lambs only) and C. perfringens type D may reduce the antibody response to vaccination in young lambs and calves. Therefore, to ensure an optimal response in young animals with high levels of MDA, the primary vaccination should be delayed until the levels wane (which is after about 8-12 weeks of age).
Do not mix with any other vaccine, immunological or veterinary medicinal products.
No information is available on the compatibility of this vaccine with any other. Therefore the safety and efficacy of this product when used with any other (either when used on the same day or at different times) has not been demonstrated.
Operator warnings
In the case of accidental self-injection, encourage bleeding and wash the area immediately with water. If a local reaction develops, seek medical advice showing the package insert or the label to the physician.
Withdrawal period: Zero days.
For animal treatment only. Keep out of the reach and sight of children.
Pharmaceutical precautions
Store and transport between +2°C and +8°C. Protect from light. Do not freeze.
Do not use after the expiry date, which is stated on the bottle label and the carton after ‘EXP’.
Shelf-life after first opening the container
Part used containers of the vaccine should be discarded within 8 hours of first opening. Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
|
